Kuros Biosciences AG Share Price Swiss Exchange
Equities
CH0325814116
Biotechnology & Medical Research
Sales 2022 | 17.99M 19.67M 1.58B | Sales 2023 | 33.56M 36.7M 2.94B | Capitalization | 128M 140M 11.24B |
---|---|---|---|---|---|
Net income 2022 | -14M -15.31M -1.23B | Net income 2023 | -13M -14.21M -1.14B | EV / Sales 2022 | 1.76 x |
Net cash position 2022 | 22.08M 24.15M 1.93B | Net cash position 2023 | 12M 13.12M 1.05B | EV / Sales 2023 | 3.46 x |
P/E ratio 2022 |
-3.41
x | P/E ratio 2023 |
-9.18
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 64.71% |
Managers | Title | Age | Since |
---|---|---|---|
Joost de Bruijn
FOU | Founder | 58 | 03/12/17 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 18/04/21 |
Daniel Geiger
DFI | Director of Finance/CFO | - | 16/02/23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Scott P. Bruder
BRD | Director/Board Member | 62 | 13/06/18 |
Christopher Fair
CEO | Chief Executive Officer | 54 | 18/04/21 |
Joost de Bruijn
FOU | Founder | 58 | 03/12/17 |
1st Jan change | Capi. | |
---|---|---|
-2.31% | 103B | |
+0.56% | 95.28B | |
+1.69% | 22.15B | |
-17.37% | 21.02B | |
-9.30% | 18.15B | |
-41.01% | 16.74B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |